Safety, tolerability and pharmacokinetics of siponimod in combination with CYP2C9/3A4 inducer, rifampin in healthy volunteers

Trial Profile

Safety, tolerability and pharmacokinetics of siponimod in combination with CYP2C9/3A4 inducer, rifampin in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Siponimod (Primary) ; Rifampicin
  • Indications Dermatomyositis; Multiple sclerosis; Polymyositis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 21 Nov 2017 New trial record
    • 28 Oct 2017 Results presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top